Author:
Li Kexun,Nie Xin,Li Changding,He Wenwu,Wang Chenghao,Du Kunyi,Li Kunzhi,Liu Kun,Li Zhiyu,Lu Simiao,Ni Kunhan,Huang Yixuan,Jiang Longlin,Wang Kangning,Li Haojun,Fang Qiang,Xiao Wenguang,Han Yongtao,Leng Xuefeng,Peng Lin
Funder
Science and Technology Department of Sichuan Province
Sichuan Province Clinical Key Specialty Construction Project
Science and Technology of Sichuan Province
Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. Global burden of disease. 2019 Cancer Collaboration, Kocarnik JM, Compton K, Dean FE, Fu W, Gaw BL, Harvey JD et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: A systematic analysis for the global burden of disease study. JAMA Oncol 2022;8(3):420-444
2. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115-132. doi:https://doi.org/10.3322/caac.21338.
3. Liang H, Fan JH, Qiao YL. Epidemiology, etiology, and prevention of esophageal squamous cell carcinoma in China. Cancer Biol Med. 2017;14(1):33-41. doi:https://doi.org/10.20892/j.issn.2095-3941.2016.0093.
4. Li C, Zhao S, Zheng Y, et al. Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1). Eur J Cancer. 2021;144:232-241. doi:https://doi.org/10.1016/j.ejca.2020.11.039.
5. Yang H, Liu H, Chen Y, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): A phase III multicenter, randomized, open-label clinical trial. J Clin Oncol. 2018;36(27):2796-2803. doi:https://doi.org/10.1200/JCO.2018.79.1483.
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献